CN114026233A - 脂质纳米颗粒 - Google Patents

脂质纳米颗粒 Download PDF

Info

Publication number
CN114026233A
CN114026233A CN202080046391.4A CN202080046391A CN114026233A CN 114026233 A CN114026233 A CN 114026233A CN 202080046391 A CN202080046391 A CN 202080046391A CN 114026233 A CN114026233 A CN 114026233A
Authority
CN
China
Prior art keywords
lipid
moiety
peg
nanoparticle
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080046391.4A
Other languages
English (en)
Chinese (zh)
Inventor
詹姆斯·海斯
亚当·贾奇
林荞梦
艾伦·D·马丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gainawan Science Co ltd
Original Assignee
Gainawan Science Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gainawan Science Co ltd filed Critical Gainawan Science Co ltd
Publication of CN114026233A publication Critical patent/CN114026233A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202080046391.4A 2019-04-26 2020-04-24 脂质纳米颗粒 Pending CN114026233A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962839452P 2019-04-26 2019-04-26
US62/839,452 2019-04-26
US201962867098P 2019-06-26 2019-06-26
US62/867,098 2019-06-26
PCT/US2020/029907 WO2020219941A1 (en) 2019-04-26 2020-04-24 Lipid nanoparticles

Publications (1)

Publication Number Publication Date
CN114026233A true CN114026233A (zh) 2022-02-08

Family

ID=72941858

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046391.4A Pending CN114026233A (zh) 2019-04-26 2020-04-24 脂质纳米颗粒

Country Status (8)

Country Link
US (1) US20220168222A1 (enExample)
EP (1) EP3959314A4 (enExample)
JP (1) JP2022530018A (enExample)
CN (1) CN114026233A (enExample)
AU (1) AU2020262437A1 (enExample)
CA (1) CA3137450A1 (enExample)
MA (1) MA55766A (enExample)
WO (1) WO2020219941A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117203186A (zh) * 2022-05-13 2023-12-08 南方科技大学 一种含有二硫键的脂质化合物及其组合物
WO2024131810A1 (en) * 2022-12-21 2024-06-27 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticles comprising sterol-modified phospholipids

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019376006A1 (en) 2018-11-09 2021-06-03 Arbutus Biopharma Corporation Cationic lipids containing silicon
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
US12023376B1 (en) 2020-04-17 2024-07-02 Triad National Security, Llc Conserved region T cell vaccines for coronavirus and methods of use
WO2022011156A1 (en) * 2020-07-10 2022-01-13 Genevant Sciences Gmbh Lipid nanoparticles for delivering therapeutics to lungs
JP2023535632A (ja) 2020-07-27 2023-08-18 アンジャリウム バイオサイエンシズ エージー Dna分子の組成物、その作製方法、及びその使用方法
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
EP4228658A4 (en) 2020-10-14 2025-02-19 George Mason Research Foundation, Inc. IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
AU2021403156A1 (en) * 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
EP4308087A4 (en) * 2021-03-17 2025-06-18 Board of Regents of the University of Nebraska LIPID NANOPARTICLE FORMULATIONS AND METHODS OF USE THEREOF
CN117203340A (zh) 2021-04-16 2023-12-08 基因泰克公司 优化的tlr7配体及其用途
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
US20240398933A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
WO2023069948A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
KR20230061895A (ko) * 2021-10-29 2023-05-09 주식회사 아이큐어비앤피 지질 나노입자 및 세포 투과성을 갖는 신규 펩타이드의 복합체
AU2023268051A1 (en) 2022-05-13 2025-01-02 BioNTech SE Rna compositions targeting hiv
WO2023230098A1 (en) 2022-05-23 2023-11-30 Logicbio Therapeutics, Inc. Gene therapy compositions and methods of use thereof
JP2025522297A (ja) 2022-05-25 2025-07-15 ビオンテック エスエー サルポックス抗原の送達のためのrna組成物及び関連する方法
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use
JP2025518221A (ja) 2022-05-30 2025-06-12 ビオンテック・ソシエタス・エウロパエア 核酸の送達のための複合体
TWI858802B (zh) * 2022-07-06 2024-10-11 南韓商綠十字股份有限公司 使用陽離子膽固醇用於核酸遞送的局部遞送的脂質納米顆粒
AU2023316579A1 (en) 2022-07-29 2025-02-13 Fujifilm Corporation COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE SIGNAL REGULATORY PROTEIN ALPHA (SIRPα) GENE
WO2024037577A1 (en) * 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
EP4642797A1 (en) 2022-12-28 2025-11-05 BioNTech SE Rna compositions targeting hiv
EP4410316A1 (en) * 2023-02-01 2024-08-07 4basebio UK Ltd Nanoparticles for delivery of nucleic acid cargos
WO2024167924A2 (en) * 2023-02-06 2024-08-15 University Of Tennessee Research Foundation Multi-functional lipid nanoparticles and uses thereof
WO2024205499A1 (en) * 2023-03-27 2024-10-03 Agency For Science, Technology And Research A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof
WO2024259158A2 (en) * 2023-06-13 2024-12-19 Cornell University Lipid nanoparticles for peptide delivery and methods of making and using the same
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
IL326647A (en) 2023-09-01 2026-04-01 Novoarc Gmbh Lipid nanoparticles with a nucleic acid charge and an ionizable lipid
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025219570A1 (en) 2024-04-17 2025-10-23 Johannes Kepler Universität Linz Composition for inhibiting protein translocation and methods using the same
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3386484T3 (pl) * 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
CN109563511A (zh) * 2016-06-30 2019-04-02 阿布特斯生物制药公司 用于递送信使rna的组合物和方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117203186A (zh) * 2022-05-13 2023-12-08 南方科技大学 一种含有二硫键的脂质化合物及其组合物
WO2024131810A1 (en) * 2022-12-21 2024-06-27 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticles comprising sterol-modified phospholipids

Also Published As

Publication number Publication date
AU2020262437A1 (en) 2021-12-23
EP3959314A4 (en) 2023-02-08
US20220168222A1 (en) 2022-06-02
EP3959314A1 (en) 2022-03-02
MA55766A (fr) 2022-03-02
WO2020219941A1 (en) 2020-10-29
CA3137450A1 (en) 2020-10-29
JP2022530018A (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
CN114026233A (zh) 脂质纳米颗粒
EP4262883B1 (en) Peg lipids and lipid nanoparticles
US12357705B2 (en) Negatively charged peg-lipid conjugates
AU2019376161B2 (en) Lipid nanoparticle formulations
JP7506670B2 (ja) 脂質ナノ粒子製剤
CN113286622A (zh) 含硅的阳离子脂质
KR20230038217A (ko) 폐에 치료제를 전달하기 위한 지질 나노입자
JP2023518944A (ja) 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
JP2025504682A (ja) ポリ(アルキルオキサゾリン)-脂質コンジュゲートおよびそれを含む脂質粒子
CA3119071C (en) Lipid nanoparticle formulations
HK40094731A (en) Peg lipids and lipid nanoparticles
HK40094731B (en) Peg lipids and lipid nanoparticles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination